UCLA Jonsson Comprehensive Cancer Center
University of California Los Angeles
Los Angeles, CA
Accepting patients
IRAK
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
- IRAK 1 Inhibitor
- IRAK 4 Inhibitor
- Phase 1/2
- Has results